The American Journal of Medicine
Volume 122, Issue 12 , Pages 1077-1084 , December 2009

Venous Thromboembolism Prophylaxis in the Medical Patient: Controversies and Perspectives

  • Alex C. Spyropoulos, MD, FACP, FCCP, FRCP(C)

      Affiliations

    • McMaster University, Hamilton, ON, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Alex C. Spyropoulos, MD, McMaster University, Hamilton General Hospital, Thrombosis Unit, 237 Barton Street East, Hamilton, ON, L8L 2X2 Canada
    • ,
  • Charles Mahan, PharmD, PhC, RPh

      Affiliations

    • Lovelace Medical Center, Albuquerque, NM

References 

  1. Geerts WH, Pineo GF, Heit J, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl):338S–400S
  2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism (The Worcester Deep Vein Thrombosis Study). Arch Intern Med. 1991;151:933–938
  3. Heit JA, Cohen AT, Anderson FA, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (venous thromboembolism) in the US. [abstract] Blood. 2005;106:Abstract 910
  4. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–I16
  5. Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–394
  6. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13:475–486
  7. Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest. 2007;132:554–561
  8. Cohen AT, Edmondson RA, Phillips RA, et al. The changing pattern of venous thromboembolic disease. Haemostasis. 1996;26:65–71
  9. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–329
  10. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132:936–945
  11. Goldhaber SZ, Tapson VF DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–262
  12. Amin A, Stemkowski S, Lin J, et al. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost. 2007;5:1610–1616
  13. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism (International Consensus Statement (guidelines according to scientific evidence)). Int Angiol. 2006;25:101–161
  14. Limpus A, Chaboyer W, McDonald E, et al. Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis. Am J Crit Care. 2006;15:402–412
  15. Lacut K, Bressollette L, Le Gal G, et al. VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage) Investigators Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology. 2005;65:865–869
  16. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S
  17. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (Prophylaxis in Medical Patients with Enoxaparin Study Group). N Engl J Med. 1999;341:793–800
  18. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  19. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146:278–288
  20. King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest. 2007;131:507–516
  21. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest. 2005;128:958–969
  22. Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1476–1486
  23. Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007;369:1347–1355
  24. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614–621
  25. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis. 1996;26(Suppl 2):49–56
  26. Alikhan R, Cohen AT. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost. 2003;89:590–591
  27. McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J. 2006;4:17–25
  28. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14–19
  29. Shorr AF, Jackson WL, Sherner JH, et al. Differences between low-molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest. 2008;133:149–155
  30. Edelsberg J, Hagiwara M, Taneja C, et al. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm. 2006;63(Suppl 6):S16–S22
  31. Spencer F, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167:1471–1475
  32. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism (venous thromboembolism) prophylaxis in acutely ill medical patients with recent reduced morbidity: the EXCLAIM study. [abstract] J Thromb Haemost. 2007;5(Suppl 2):O-S-001
  33. Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165:341–345
  34. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673–684
  35. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005;20:357–363
  36. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006;91:976–979
  37. et al Douketis J, Cook D Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008;168:1805–1812
  38. Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost. 2007;97:581–586
  39. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S–203S
  40. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15:3192–3206
  41. Venous thromboembolic event prophylaxis in medically ill patients. Clinicaltrials.gov web site http://www.clinicaltrials.gov/ct2/show/NCT00571649?term=rivaroxaban&rank=9Accessed October 31, 2008
  42. Study of apixaban for the prevention of thrombosis-related events in patients with acute medical illness. Clinicaltrials.gov web site http://clinicaltrials.gov/show/NCT00457002Accessed November 7, 2008
  43. The Joint Commission. The 2008 National Patient Safety Goals Manual Chapter. http://www.jointcommission.org/NR/rdonlyres/A391E808-AF10-4C5E-873D-CB185E2009F0/0/08_AHC_NPSGs_Master.pdfAccessed November 10, 2008
  44. The Joint Commission. Performance Measurement Initiatives (National Consensus Standards for Prevention and Care of Venous Thromboembolism (venous thromboembolism) [The Joint Commission web site]). Updated October 2008 http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/venous thromboembolism.htmAccessed November 10, 2008

 Funding: Editorial support for the manuscript was provided by Eisai Inc.

 Conflict of Interest: Dr. Spyropoulos receives consultant and speakers' fees from Eisai Inc., sanofi-aventis, Bayer, and Astellas. Dr. Mahan receives consultant and speaker fees from sanofi-aventis and Eisai Inc.

 Authorship: Both authors had access to all the data and a role in writing the manuscript.

PII: S0002-9343(09)00776-1

doi: 10.1016/j.amjmed.2009.04.027

The American Journal of Medicine
Volume 122, Issue 12 , Pages 1077-1084 , December 2009

Article Tools